ArticleFrontiers in microbiology2022
Emergence of a novel hybrid
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Detection and Genomic Characteristics of NDM-19- and QnrS11-Producing O101:H5Microorganisms · 2025Article
- One Health at Risk: Plasmid-Mediated Spread ofAntibiotics (Basel, Switzerland) · 2025Review
- Detection of a genetically related carbapenemase-producing Escherichia coli ST167 in clinical and environmental isolates: Evidence for clonal spread of carbapenemase-producing Enterobacteriaceae in humans and the environment in Iowa, United States.Journal of global antimicrobial resistance · 2025Article
- Emerging Mobile Colistin Resistance GeneInfection and drug resistance · 2025Article
- Polyclonal carbapenemase-producingFrontiers in cellular and infection microbiology · 2025Article
- Identification and Genomic Analyses of a Multidrug Resistant Avian PathogenicTransboundary and emerging diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin is considered as an antibiotic of 'last resort' for the treatment of lethal infections caused by carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.